Functional characterization of an activating TEK mutation in acute myeloid leukemia: A cellular context-dependent activating mutation

Leukemia

Volumn 23, Issue 7, 2009, Pages 1345-1348

  Tyner, J W ^a   Rutenberg Schoenberg, M L ^a   Erickson, H ^a   Willis, S G ^a   O'Hare, T ^a,b   Deininger, M W ^a   Druker, B J ^a,b   Loriaux, M M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANGIOPOIETIN 1; GUANOSINE; INTERLEUKIN 3; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN TEK; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ANIMAL CELL; CANCER CELL; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LETTER; LEUKEMOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 67650875891     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.66     Document Type: Letter

References (16)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
4. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007; 369: 29-36.
5. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
6. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001; 15: 1923-1931.
7. Hayakawa F, Towatari M, Iida H, Wakao H, Kiyoi H, Naoe T et al. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol 1998; 101: 521-528.
8. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002; 30: 262-271.
9. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158.
10. Loriaux MM, Levine RL, Tyner JW, Frohling S, Scholl C, Stoffregen EP et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008; 111: 4788-4796.
11. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
12. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111: 4797-4808.
13. Morris PN, Dunmore BJ, Tadros A, Marchuk DA, Darland DC, D'Amore PA et al. Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations. J Mol Med 2005; 83 58-63.
14. Wang H, Zhang Y, Toratani S, Okamoto T. Transformation of vascular endothelial cells by a point mutation in the Tie2 gene from human intramuscular haemangioma. Oncogene 2004; 23: 8700-8704.
15. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 2008; 40: 722-729.
16. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A et al The complete genome of an individual by massively parallel DNA sequencing. Nature 2008; 452: 872-876.